Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetaminophen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.83 |
| ▸ | CA2 | P00918 | 5/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | CA9 | Q16790 | 4/20 | 0.83 |
| ▸ | CA12 | O43570 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | BRD4 | O60885 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | MB | P02144 | 1/20 | 0.83 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.83 |
| ▸ | CA3 | P07451 | 1/20 | 0.83 |
| ▸ | RARG | P13631 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.83 |
| ▸ | CA4 | P22748 | 1/20 | 0.83 |
| ▸ | CA7 | P43166 | 1/20 | 0.83 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaminophen SCHEMBL3480 | 0.91 | KMT2A (1.00) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL252939 | 0.91 | KMT2A (1.00) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL8937727 | 0.91 | KMT2A (1.00) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL28672184 | 0.90 | CA1 (0.80) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL8959271 | 0.89 | KMT2A (0.95) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL10325382 | 0.89 | KMT2A (0.95) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL8207526 | 0.89 | KMT2A (0.95) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL20541508 | 0.89 | ALDH1A1 (0.95) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL8197085 | 0.89 | KMT2A (0.95) | CA1CA2ALDH1A1CA9CA12 | |
| Acetaminophen SCHEMBL5081499 | 0.89 | KMT2A (0.95) | CA1CA2ALDH1A1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| JP-4173745-A | — | — | None | — | — | JP | disclosed |
| US-12560617-B2 | Method of diagnosing and treatment monitoring of crohn's disease and ulcerative colitis | MCMASTER UNIVERSITY (CA) | 2026-02-24 | — | — | US | disclosed |
| CN-119655374-A | Active substance for strengthening cardiovascular functions of dogs and cats, and preparation method and application of soft capsule | 卫仕宠物营养研究院(芜湖)有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023219593-A1 | TABLET COMPOSITION COMPRISING PARACETAMOL AND ASCORBIC ACID | ATABAY KIMYA SANAYI VE TIC. A.S. (TR) | 2023-11-16 | — | — | WO | disclosed |
| US-20230139291-A1 | EXPANSION AND MAINTENANCE OF ADULT PRIMARY HUMAN HEPATOCYTES IN CULTURE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230123695-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3484483-B1 | GLYCAN COMPOSITIONS AND METHODS OF USE | KALEIDO BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11566229-B2 | Expansion and maintenance of adult primary human hepatocytes in culture | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20020145425-A1 | Methods for spectral analysis and their applications: spectral replacement | METABOMETRIX LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002052293-A1 | METHODS FOR SPECTRAL ANALYSIS AND THEIR APPLICATIONS: SPECTRAL REPLACEMENT | METABOMETRIX LIMITED (GB) | 2002-07-04 | — | — | WO | disclosed |
| WO-2001096895-A1 | METHOD FOR INVESTIGATING THE FATE OF A TEST COMPOUND OR THE STATEOF A BIOLOGICAL SYSTEM BY MEANS OF NMR OF HYPERPOLARISED NMR ACTIVE NUCLEI | AMERSHAM PLC (GB) | 2001-12-20 | — | — | WO | disclosed |
| US-5474757-A | Administering diallyl sulfone to prevent metabolism of acetaminophen into hepatotoxic metabolites | RUTGERS UNIVERSITY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994008628-A1 | PREVENTION OF ACETAMINOPHEN OVERDOSE TOXICITY WITH ORGANOSULFUR COMPOUNDS | RUTGERS UNIVERSITY (US) | 1994-04-28 | — | — | WO | disclosed |
| JP-H04173745-A | TISSUE TRANSITION PROMOTER OF MEDICINE CONSISTING OF P-ACETYLAMINOPHENOL SULFATE SALT | NAKAYAMA TAIJI | 1992-06-22 | — | — | JP | disclosed |
| US-4520134-A | ANALGESICS | ROSEN GERALD M (US) | 1985-05-28 | — | — | US | disclosed |
| US-4424150-A | Acetaminophen analogs, antigens, and antibodies | SYVA COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4314989-A | Methionine sulfoxide amflioration of acetaminophen toxicity | ROSEN GERALD M | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12560617-B2 | Method of diagnosing and treatment monitoring of crohn's disease and ulcerative colitis | AADAT, GNMT, HNMT | CA1 444/4885CA2 1157/4885ALDH1A1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.